Compare ADMA Biologics Inc (ADMA) vs Gold Fields Limited (GFI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Gold Fields Limited — how do they compare? ADMA Biologics Inc trades at $9.27 (market cap $2.13B), while Gold Fields Limited trades at $32.9 (market cap $30.01B). The key difference: Gold Fields Limited is far larger — about 14.1× ADMA Biologics Inc's market cap, and Gold Fields Limited pays a 6.91% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | GFI | |
|---|---|---|
Market Cap | $2.13B | $30.01B |
Sector | Health | Basic Materials |
52-Week High | $20.38 | $61.52 |
52-Week Low | $7.60 | $23.36 |
Enterprise Value | $2.20B | $31.46B |
Dividend Yield | — | 6.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Gold Fields (GFI) trades at $33.58, down 5.3% over 24 hours, reflecting recent bearish technical momentum. The stock shows strong fundamentals with a P/E of 8.78 and robust profitability margins, including a 40.76% net income margin. Recent earnings have been mixed, with a Q1 2025 beat but subsequent misses. Cash flow improved significantly in 2025, and the balance sheet remains solid despite rising debt levels. Analyst sentiment is divided with a 44% buy rating amid operational challenges and gold price volatility.
The outlook for GFI hinges on execution at key mines like Salares Norte and gold price stability. Upside potential exists from strong cash generation and shareholder returns, but risks include cost inflation and geopolitical pressures. The current valuation appears attractive if operational targets are met, though near-term volatility may persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →
